Skip to main content

Peritonitis

1
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
Pro-bioticsPhase 41 trial
Active Trials
NCT01076426Unknown100Est. Mar 2011
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
DalbavancinN/A1 trial
Active Trials
NCT04624451Terminated2Est. Jan 2024
Pfizer
PfizerNEW YORK, NY
1 program
TygacilN/A1 trial
Active Trials
NCT00481962Completed180Est. Dec 2008
Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
Pentaglobin®/Standard of CarePHASE_21 trial
Active Trials
NCT03334006Recruiting200Est. Mar 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BiocorpPro-biotics
Biotest PharmaceuticalsPentaglobin®/Standard of Care
Colorado TherapeuticsDalbavancin
PfizerTygacil

Clinical Trials (4)

Total enrollment: 482 patients across 4 trials

NCT01076426BiocorpPro-biotics

Probiotics Use in the Chronic Peritoneal Dialysis Patients

Start: Feb 2010Est. completion: Mar 2011100 patients
Phase 4Unknown
NCT03334006Biotest PharmaceuticalsPentaglobin®/Standard of Care

Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis

Start: Nov 2017Est. completion: Mar 2028200 patients
Phase 2Recruiting
NCT04624451Colorado TherapeuticsDalbavancin

Evaluation of Intravenous Dalbavancin for Peritonitis

Start: Jun 2020Est. completion: Jan 20242 patients
N/ATerminated
NCT00481962PfizerTygacil

Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)

Start: Feb 2006Est. completion: Dec 2008180 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 482 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.